IP Library Granted Patent US 6,962,908
Granted Patent B2
US 6,962,908 · App. 10/023,748 · Granted Nov 8, 2005

Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,962,908
App. No.
10/023,748
Granted
Nov 8, 2005
Kind
B2
Abstract

A pharmaceutical dosage unit for oral administration to a human female comprising a therapeutically effective amount of 17β-estradiol-3-lower alkanoate, most preferably 17β-estradiol-3-acetate, and a pharmaceutically acceptable carrier is disclosed. Also disclosed is a method for treating a human female in need of 17β-estradiol and a contraceptive method by oral administration of the pharmaceutical dosage unit and a method of preparing a pharmaceutical composition that may be used to form the pharmaceutical dosage unit of the invention.

Claims (7)

1. A pharmaceutical solid dosage unit for oral administration to a human female comprising a therapeutically effective amount of 17β-estradiol-3-acetate and a pharmaceutically acceptable carrier, wherein the percent moisture of said dosage unit is less than or equial to 8%, the amount of 17β-3-estradiol-3-acetate is from about 0.1 to about 10 mg as estradiol equivalent and the solid dosage unit further comprises a pharmaceutically acceptable inhibitor of ester hydrolysis that is acetic acid.

2. The dosage unit according to claim 1 , wherein the percent moisture of said dosage unit is less than 5%.

3. The dosage unit according to claim 1 , further comprising one or more additional steroids.

4. The dosage unit according to claim 3 , wherein said one or more steroids have progestational activity.

5. The dosage unit according to claim 2 , wherein the dosage unit is prepared by a granulation method.

6. The dosage unit according to claim 1 , wherein the dosage unit is a tablet, capsule, powder, lozenge, or troche.

7. The dosage unit according to claim 1 , wherein the dosage unit is a tablet or capsule.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2021
From: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
To: ALLERGAN THERAPEUTICS LLC
Reel/Frame 057605/0461 →
CORRECTIVE ASSIGNMENT TO CORRECT THE US PATENT NO. 8,050,873 PREVIOUSLY RECORDED ON REEL 040183 FRAME 0129. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 22, 2018
From: WARNER CHILCOTT COMPANY, LLC
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 045417/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2016
From: WARNER CHILCOTT COMPANY, LLC
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 040183/0129 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2013
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 031531/0538 →
RELEASE - REEL 023456, FRAME 0052 Recorded Mar 29, 2011
From: CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT COMPANY LLC
Reel/Frame 026042/0046 →
CHANGE OF NAME Recorded Jun 18, 2009
From: WARNER CHILCOTT COMPANY, INC.
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 022835/0896 →